<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03006835</url>
  </required_header>
  <id_info>
    <org_study_id>ky20162060-2</org_study_id>
    <nct_id>NCT03006835</nct_id>
  </id_info>
  <brief_title>Different Dosage of Domestic and Imported Clopidogrel on the Platelet Inhibition Ratio in Patients Undergoing PCI</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xijing Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Shenzhen Salubris Pharmaceuticals Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Xijing Hospital</source>
  <brief_summary>
    <textblock>
      This is a single-center, randomized, single-blind, investigator-initiated, pharmacological&#xD;
      study with a parallel design. Patients with non-ACS undergoing primary percutaneous coronary&#xD;
      intervention will be randomized after informed consent, in a 1:1:1:1 ratio to the following&#xD;
      treatment groups:&#xD;
&#xD;
      Group Α: Domestic Clopidogrel 300mg as a loading dose before PCI, followed by 75mg per day.&#xD;
&#xD;
      Group B: Domestic Clopidogrel 600mg as a loading dose before PCI, followed by 75mg per day.&#xD;
&#xD;
      Group B: Imported Clopidogrel 300mg as a loading dose before PCI, followed by 75mg per day.&#xD;
&#xD;
      Group D: Imported Clopidogrel 600mg as a loading dose before PCI, followed by 75mg per day.&#xD;
&#xD;
      Platelet inhibition ratio assessment by thrombelastogram will be performed，2 hours after the&#xD;
      loading dose(Day 0)， 6 hours after thrombelastogram (Day 0), 30 day after thrombelastogram.&#xD;
      Documentation of major adverse cardiac events (death, myocardial infarction, stroke,&#xD;
      revascularization procedure with PCI or CABG) and serious adverse events (bleeding, other&#xD;
      adverse events)will be performed until Day 30.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>January 2017</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ADP- induced platelet inhibition rate</measure>
    <time_frame>2 hours after the loading dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>ADP- induced platelet inhibition rate</measure>
    <time_frame>6 hours after the loading dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>ADP- induced platelet inhibition rate</measure>
    <time_frame>30 days after the loading dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>R value (min)</measure>
    <time_frame>2 hours after the loading dose</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Coronary Heart Disease</condition>
  <arm_group>
    <arm_group_label>Domestic Clopidogrel 300mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Domestic Clopidogrel 300mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Domestic Clopidogrel 600mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Domestic Clopidogrel 600mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Imported Clopidogrel 300mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Imported Clopidogrel 300mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Imported Clopidogrel 600mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Imported Clopidogrel 600mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clopidogrel</intervention_name>
    <arm_group_label>Domestic Clopidogrel 300mg</arm_group_label>
    <arm_group_label>Domestic Clopidogrel 600mg</arm_group_label>
    <arm_group_label>Imported Clopidogrel 300mg</arm_group_label>
    <arm_group_label>Imported Clopidogrel 600mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. The patient is scheduled to undergo non-urgent PCI&#xD;
&#xD;
          2. The patient is between 18 and 75 years of age (inclusive) and willing to comply with&#xD;
             the protocol&#xD;
&#xD;
          3. The patient or legally acceptable representative is able to read and give written&#xD;
             informed consent and has signed an informed consent form approved by the&#xD;
             Investigator's IRB/IEC&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Estimated or measured weight &lt; 55 kg&#xD;
&#xD;
          2. Acute non-ST-segment elevation myocardial infarction (NSTEMI) or ST-segment elevation&#xD;
             myocardial infarction (STEMI) within 7 days prior to PCI&#xD;
&#xD;
          3. Uncontrolled hypertension at the time of initial study drug administration defined as&#xD;
             measured systolic blood pressure &gt; 190 mm Hg or diastolic blood pressure &gt; 108 mm Hg&#xD;
&#xD;
          4. Patient has received a clopidogrel loading dose (≥300 mg) within 30 days prior to&#xD;
             randomization; patients on maintenance clopidogrel may be enrolled&#xD;
&#xD;
          5. Administration of thrombolytic agents, fondaparinux, or oral anticoagulants (e.g.,&#xD;
             warfarin) within the 7 days prior to PCI&#xD;
&#xD;
          6. Estimated creatinine clearance (e.g. Cockcroft-Gault) &lt; 45 mL/min&#xD;
&#xD;
          7. Anemia with hemoglobin level &lt; 10 g/dL&#xD;
&#xD;
          8. Thrombocytopenia (platelet count &lt; 100,000/mm3)&#xD;
&#xD;
          9. ALT and/or AST &gt; 2.5 x the ULN or other indication of clinically significant hepatic&#xD;
             dysfunction&#xD;
&#xD;
         10. Facial or head trauma within the last 30 days&#xD;
&#xD;
         11. Intraocular hemorrhage within the last 30 days&#xD;
&#xD;
         12. Gastrointestinal bleeding within the last 30 days&#xD;
&#xD;
         13. Active bleeding, or history of a bleeding disorder or known intracranial vascular&#xD;
             malformation&#xD;
&#xD;
         14. Known allergy or contraindication to aspirin, heparin, clopidogrel, or to any contrast&#xD;
             media&#xD;
&#xD;
         15. Participation in any investigational drug study within 30 days prior to enrollment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>ruining zhang, doctor</last_name>
    <role>Study Director</role>
    <affiliation>Xijing Hospital, The Fourth Military Medical University, 15 Changle West Road, Xi'an, 710032, China</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>yi liu, doctor</last_name>
    <phone>86-029-84775183</phone>
    <email>1391643423@qq.com</email>
  </overall_contact>
  <verification_date>December 2016</verification_date>
  <study_first_submitted>December 27, 2016</study_first_submitted>
  <study_first_submitted_qc>December 27, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 30, 2016</study_first_posted>
  <last_update_submitted>December 27, 2016</last_update_submitted>
  <last_update_submitted_qc>December 27, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 30, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Clopidogrel; Platelet Inhibition Ratio</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clopidogrel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

